[
  {
    "date": "2023-12-30",
    "symbol": "CANF",
    "period": "FY",
    "cashandcashequivalentsatcarryingvalue": 4278000,
    "depositsassetscurrent": 4625000,
    "prepaidexpenseandotherassetscurrent": 986000,
    "shortterminvestments": 19000,
    "assetscurrent": 9908000,
    "operatingleaserightofuseasset": 52000,
    "propertyplantandequipmentnet": 29000,
    "assetsnoncurrent": 81000,
    "assets": 9989000,
    "accountspayabletradecurrent": 427000,
    "operatingleaseliabilitycurrent": 27000,
    "contractwithcustomerliabilitycurrent": 622000,
    "accountspayableandotheraccruedliabilitiescurrent": 944000,
    "liabilitiescurrent": 2020000,
    "operatingleaseliabilitynoncurrent": 13000,
    "contractwithcustomerliabilitynoncurrent": 1713000,
    "liabilitiesnoncurrent": 1726000,
    "additionalpaidincapital": 163597000,
    "accumulatedothercomprehensiveincomelossnetoftax": 1127000,
    "retainedearningsaccumulateddeficit": -158481000,
    "stockholdersequity": 6243000,
    "liabilitiesandstockholdersequity": 9989000,
    "commonstocksharesauthorized": 5000000000,
    "commonstocksharesissued": 1359837393,
    "commonstocksharesoutstanding": 1359837393,
    "revenuefromcontractwithcustomerincludingassessedtax": 743000,
    "researchanddevelopmentexpense": 5983000,
    "generalandadministrativeexpense": 2955000,
    "operatingincomeloss": -8195000,
    "nonoperatingincomeexpense": 561000,
    "incomelossfromcontinuingoperationsbeforeincometaxesextraordinaryitemsnoncontrollinginterest": -7634000,
    "netincomeloss": -7634000,
    "comprehensiveincomenetoftaxincludingportionattributabletononcontrollinginterest": -7634000,
    "earningspersharebasic": -0.01,
    "weightedaveragenumberofsharesoutstandingbasic": 1278333912,
    "earningspersharediluted": -0.01,
    "weightedaveragenumberofdilutedsharesoutstanding": 1278333912,
    "issuanceofsharecapitalduetowarrantsexercisenetofissuanceexpenses": 2618000,
    "issuanceofsharecapitalduetowarrantsexercisenetofissuanceexpensesinshares": 454091100,
    "stockissuedduringperiodvalueissuanceofsharecapitalandwarrants": 6526000,
    "stockissuedduringperiodshareissuanceofsharecapitalandwarrants": 90000000,
    "adjustmentstoadditionalpaidincapitalsharebasedcompensationstockoptionsrequisiteserviceperiodrecognition": 261000,
    "debtinstrumentunamortizeddiscountpremiumanddebtissuancecostsnet": 386000,
    "warrantsnetofissuanceexpenses": 973000,
    "depreciation": 15000,
    "operatingleaserightofuseassetamortizationexpense": 94000,
    "sharebasedcompensation": 261000,
    "increasedecreaseinchangesinfairvalueofshortterminvestment": 11000,
    "othernoncashincomeexpense": 222000,
    "increasedecreaseinprepaiddeferredexpenseandotherassets": -184000,
    "increasedecreaseinoperatingleaseliability": -84000,
    "increasedecreaseinaccountspayabletrade": -469000,
    "increasedecreaseincontractwithcustomerliability": -743000,
    "increasedecreaseinotheraccountspayable": 169000,
    "netcashprovidedbyusedinoperatingactivities": -8440000,
    "paymentstoacquirepropertyplantandequipment": 2000,
    "withdrawalinvestmentinshorttermdepositsnet": -500000,
    "netcashprovidedbyusedininvestingactivities": 498000,
    "proceedsfromissuanceofsharesunderincentiveandsharebasedcompensationplansincludingstockoptions": 9144000,
    "netcashprovidedbyusedinfinancingactivities": 9144000,
    "effectofexchangerateoncashcashequivalentsrestrictedcashandrestrictedcashequivalents": 98000,
    "cashcashequivalentsrestrictedcashandrestrictedcashequivalentsperiodincreasedecreaseincludingexchangerateeffect": 1300000,
    "cashcashequivalentsrestrictedcashandrestrictedcashequivalentsincludingdisposalgroupanddiscontinuedoperations": 4278000,
    "rightofuseassetobtainedinexchangeforoperatingleaseliability": 62000,
    "prepaidexpensesandothercurrentassetspolicytextblock": "f.Prepaid expenses, and other current assets",
    "severancepaypolicytextblock": "o. Severance pay:",
    "ordinarysharewarrantsclassificationandmeasurementpolicytextblock": "r.Warrants to purchase ordinary shares:",
    "scheduleofusefullivesoftheassetstabletextblock": "Property and equipment are stated atcost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of theassets at the following annual rates:",
    "usefullivesordepreciationratespropertyplantandequipments": 0.1,
    "concentrationriskpercentage1": 0.11,
    "antidilutivesecuritiesexcludedfromcomputationofearningspershareamount": 82477000,
    "governmentauthorities": 78000,
    "prepaidexpensecurrent": 908000,
    "propertyplantandequipmentgross": 62000,
    "accumulateddepreciationdepletionandamortizationpropertyplantandequipment": 48000,
    "employeerelatedliabilitiescurrent": 694000,
    "otheraccruedliabilitiescurrent": 250000,
    "accountspayableothercurrent": 944000,
    "issuancedate": "January 2019",
    "classofwarrantorrightoutstanding": 109091100,
    "classofwarrantorrightexercisepriceofwarrantsorrights1": 0.65,
    "allocatedsharebasedcompensationexpense": 83000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsriskfreeinterestrate": 0.0395,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsexpectedvolatilityrate": 0.843,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsexpectedterm1": "P10Y",
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionexerciseprice": 2.5,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsgrantsinperiodgross": 55500000,
    "sharebasedcompensationarrangementsbysharebasedpaymentawardoptionsgrantsinperiodweightedaverageexerciseprice": 0.01,
    "weightedaverageremainingcontractualtermsgeants": "P10Y",
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsforfeituresandexpirationsinperiod": 25200,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingnumber": 82477000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageexerciseprice": 0.04,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageremainingcontractualterm2": "P8Y4M24D",
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsvestedandexpectedtovestoutstandingnumber": 82477000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsvestedandexpectedtovestoutstandingweightedaverageexerciseprice": 0.04,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsvestedandexpectedtovestoutstandingweightedaverageremainingcontractualterm1": "P8Y4M24D",
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsvestedandexpectedtovestexercisablenumber": 24280125,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsvestedandexpectedtovestexercisableweightedaverageexerciseprice": 0.11,
    "sharebasedcompensationsharesauthorizedunderstockoptionplansexercisepricerangeexercisableoptionsweightedaverageremainingcontractualterm2": "P7Y2M15D",
    "operatingleaseweightedaverageremainingleaseterm1": "P1Y7M6D",
    "operatingleaseweightedaveragediscountratepercent": 0.13,
    "operatingleasecost": 56000,
    "operatingleasepayments": 56000,
    "lesseeoperatingleaseliabilitypaymentsduenexttwelvemonths": 25000,
    "lesseeoperatingleaseliabilitypaymentsdueyeartwo": 14000,
    "lesseeoperatingleaseliabilitypaymentsdueyearthree": 3000,
    "lesseeoperatingleaseliabilitypaymentsdue": 42000,
    "lesseeoperatingleaseliabilityundiscountedexcessamount": 2000,
    "operatingleaseliability": 40000,
    "interestincomedepositswithfinancialinstitutions": 506000,
    "bankscommissions": 14000,
    "exchangeratefluctuations": 58000,
    "othergainfromshortterminvestmentremeasurement": 11000,
    "othernonoperatingincomeexpense": 561000,
    "deferredtaxassetsoperatinglosscarryforwards": 25606000,
    "deferredtaxassetsinprocessresearchanddevelopment": 1056000,
    "deferredtaxassetsgross": 26662000,
    "deferredtaxassetsvaluationallowance": 26662000,
    "sharesissued": 300,
    "cashcashequivalentsandshortterminvestments": 8903000,
    "shorttermbankdepositsyearlyinterestratepercentage": 0.06,
    "contractwithcustomerliability": 2335000,
    "percentageofdepositsonmonthlysalary": 0.0833,
    "severancecosts1": 47000,
    "percentageofrealizationonultimatesettlement": 0.5,
    "investmentownedbalanceshares": 5947,
    "revenueperformanceobligationdescriptionofpaymentterms": "In addition, the agreement provides that additional paymentsof up to 2,000 Canadian Dollar will be received by the Company upon the achievement of certain milestones plus royalty payments of 16.5%of net sales of Piclidenoson in Canada.",
    "additionalrevenuereceivedforachievedmilestone": 500,
    "noninterestexpensecommissionexpense": 25000,
    "royaltyexpense": 10000,
    "percentageofnetsales": 0.02,
    "patentagreementdescription": "Royalties in a total amount of up to €850 thousand based on certain progress milestones in the license stages of the products, which are the subject of the patent under the agreement, as follows: (i) €50 thousand upon initiation of Phase I studies; (ii) €100 thousand upon initiation of Phase II studies; (iii) €200 thousand upon initiation of Phase III studies; and (iv) €500 thousand upon marketing approval by any regulatory authority.",
    "advanceroyalties": 850000,
    "royaltypaymentspercentage": 0.1,
    "aggregatewarrantpurchased": 0.022,
    "stockoptionexercisepriceincrease": 0.018,
    "exerciseagreementdescription": "The Private Placement Warrants will be immediately exercisable, will expire five years following the effectiveness ofan initial resale registration statement registering the ADSs issuable upon the exercise of the warrants, and have an exercise price of$0.07 per Ordinary share. The Company also paid $875 in placement agent fees and issued unregistered placement agent warrants to purchase10,500,000 Ordinary shares on the same terms as the warrant.",
    "issueofnewunregisteredwarrants": 109091100,
    "sharebasedcompensationarrangementbysharebasedpaymentawardpershareweightedaveragepriceofsharespurchased": 0.018,
    "warrantexercisepriceincrease": 0.02,
    "otheradditionalcapital": 973000,
    "deferredfinancecostsnet": 6526000,
    "classofwarrantorrightnumberofsecuritiescalledbywarrantsorrights": 319091100,
    "sharesoutstanding": 135000000,
    "classofwarrantorrightnumberofsecuritiescalledbywarrantorrights": 1178182200,
    "futureshares": 100000000,
    "sharebasedcompensationsharesauthorizedunderstockoptionplansexercisepricerangeoutstandingoptionsweightedaverageremainingcontractualterm2": "P5Y10M17D",
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsvestedweightedaveragegrantdatefairvalue": 0.01,
    "employeeservicesharebasedcompensationnonvestedawardstotalcompensationcostnotyetrecognized": 298000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsoutstandingweightedaverageremainingcontractualterms": "P3Y1M6D",
    "lesseeoperatingleasetermofcontract": "P3Y",
    "effectiveincometaxratecontinuingoperations": 0.23,
    "effectiveincometaxratereconciliationatfederalstatutoryincometaxrate": 0.16,
    "developmentareaapercentage": 0.075,
    "operatinglosscarryforwards": 160035000,
    "costsandexpensesrelatedparty": 237000,
    "documenttype": "20-F",
    "documentregistrationstatement": "false",
    "documentannualreport": "true",
    "documenttransitionreport": "false",
    "documentfinstmterrorcorrectionflag": "false",
    "documentshellcompanyreport": "false",
    "entityinteractivedatacurrent": "Yes",
    "documentaccountingstandard": "U.S. GAAP",
    "icfrauditorattestationflag": "false",
    "amendmentflag": "false",
    "documentperiodenddate": "2023-12-31",
    "documentfiscalyearfocus": 2023,
    "documentfiscalperiodfocus": "FY",
    "entityregistrantname": "Can-Fite BioPharma Ltd.",
    "entitycentralindexkey": 1536196,
    "entityfilenumber": "001-36203",
    "entityincorporationstatecountrycode": "L3",
    "currentfiscalyearenddate": "--12-31",
    "entitywellknownseasonedissuer": "No",
    "entityvoluntaryfilers": "No",
    "entitycurrentreportingstatus": "Yes",
    "entityshellcompany": "false",
    "entityfilercategory": "Non-accelerated Filer",
    "entityemerginggrowthcompany": "false",
    "contactpersonnelname": "Motti Farbstein",
    "contactpersonnelemailaddress": "motti@canfite.co.il",
    "contactpersonnelfaxnumber": "972 (3) 924-9378",
    "entityaddressaddressline1": "26 Ben Gurion Street",
    "entityaddresscityortown": "Ramat Gan",
    "entityaddresscountry": "IL",
    "entityaddresspostalzipcode": 5257346,
    "cityareacode": 972,
    "localphonenumber": "(3) 924-1114",
    "security12btitle": "American Depositary Shares, each representing 300 Ordinary Shares, no par value",
    "tradingsymbol": "CANF",
    "securityexchangename": "NYSEAMER",
    "entitycommonstocksharesoutstanding": 1359837393,
    "auditorname": "KOST FORER GABBAY& KASIERER",
    "auditorfirmid": 1281,
    "auditorlocation": "Tel-Aviv, Israel"
  },
  {
    "date": "2022-12-31",
    "symbol": "CANF",
    "period": "FY",
    "cashandcashequivalentsatcarryingvalue": 2978000,
    "depositsassetscurrent": 5001000,
    "prepaidexpenseandotherassetscurrent": 1170000,
    "shortterminvestments": 8000,
    "assetscurrent": 9157000,
    "operatingleaserightofuseasset": 84000,
    "propertyplantandequipmentnet": 42000,
    "assetsnoncurrent": 126000,
    "assets": 9283000,
    "accountspayabletradecurrent": 896000,
    "operatingleaseliabilitycurrent": 48000,
    "deferredrevenuecurrent": 783000,
    "accountspayableandotheraccruedliabilitiescurrent": 775000,
    "liabilitiescurrent": 2502000,
    "operatingleaseliabilitynoncurrent": 14000,
    "deferredrevenuenoncurrent": 2295000,
    "liabilitiesnoncurrent": 2309000,
    "additionalpaidincapital": 154192000,
    "accumulatedothercomprehensiveincomelossnetoftax": 1127000,
    "retainedearningsaccumulateddeficit": -150847000,
    "stockholdersequity": -150847000,
    "liabilitiesandstockholdersequity": 9283000,
    "commonstocksharesauthorized": 5000000000,
    "commonstocksharesissued": 815746293,
    "commonstocksharesoutstanding": 815746293,
    "revenues": 810000,
    "researchanddevelopmentexpense": 7763000,
    "generalandadministrativeexpense": 3143000,
    "operatingincomeloss": -10096000,
    "nonoperatingincomeexpense": -77000,
    "incomelossfromcontinuingoperationsbeforeincometaxesextraordinaryitemsnoncontrollinginterest": -10173000,
    "netincomeloss": -10173000,
    "comprehensiveincomenetoftaxincludingportionattributabletononcontrollinginterest": -10173000,
    "earningspersharebasic": -0.01,
    "weightedaveragenumberofsharesoutstandingbasic": 815746293,
    "earningspersharediluted": -0.01,
    "weightedaveragenumberofdilutedsharesoutstanding": 815746293,
    "sharesoutstanding": 815746293,
    "stockissuedduringperiodvaluesharebasedcompensation": 263000,
    "depreciationdepletionandamortization": 14000,
    "increasedecreaseinotheroperatingassets": -54000,
    "sharebasedcompensation": 263000,
    "increasedecreaseinchangesinfairvalueofshortterminvestment": -229000,
    "othernoncashincomeexpense": -113000,
    "increasedecreaseinprepaiddeferredexpenseandotherassets": 241000,
    "increasedecreaseinotheroperatingliabilities": -62000,
    "increasedecreaseinaccountspayabletrade": -58000,
    "increasedecreaseindeferredrevenue": -810000,
    "increasedecreaseinotheraccountspayable": -130000,
    "netcashprovidedbyusedinoperatingactivities": -10801000,
    "paymentstoacquirepropertyplantandequipment": 9000,
    "withdrawalinvestmentinshorttermdepositsnet": -9511000,
    "netcashprovidedbyusedininvestingactivities": 9502000,
    "effectofexchangerateoncashcashequivalentsrestrictedcashandrestrictedcashequivalents": -113000,
    "cashcashequivalentsrestrictedcashandrestrictedcashequivalentsperiodincreasedecreaseincludingexchangerateeffect": -1412000,
    "cashcashequivalentsrestrictedcashandrestrictedcashequivalentsincludingdisposalgroupanddiscontinuedoperations": 2978000,
    "severancepaypolicytextblock": "    o. Severance pay:  ",
    "ordinarysharewarrantsclassificationandmeasurementpolicytextblock": "r.Ordinary share and warrants classification and measurement: ",
    "scheduleofusefullivesoftheassetstabletextblock": "            %      Mainly %                            Laboratory equipment     10      10                            Computers, office furniture and equipment     6 - 33      33    ",
    "scheduleofmajorcustomerdataasapercentageoftotalrevenuestabletextblock": "            Year ended December 31,             2022      2021      2020                                   Cipher Pharmaceuticals (Canada)      11%      12%      20%      Chong Kun Dang Pharmaceuticals Corp. (South Korea)      25%      24%      45%      Gebro Holding GmbH (Austria)      18%      23%      35%      Ewopharma AG (Switzerland)      46%      41%      -                                       Total      100%      100%      100%   ",
    "scheduleofexpensestabletextblock": "            Year ended December 31,             2022      2021      2020                                   Research and development expenses     $137      $200      $159       General and administrative expenses      126       266       158              263       466       317    ",
    "scheduleofestimatedusingthebinomialoptionpricingmodeltabletextblock": "      Description     2022      2021      2020                                   Risk-free interest rate      1.41%-3.08%       1.22-1.28%       0.93-2.40%       Expected volatility      83.98%-84.26%        82.40-82.43%       65.63-78.77%       Dividend yield      0       0       0       Contractual life      10       10       9.83 - 10       Early Exercise Multiple (Suboptimal Factor)      2.5-3       3       2.5 - 3       Exercise price (NIS)      0.25       0.25-0.253       0.25 - 2.344    ",
    "usefullivesordepreciationratespropertyplantandequipments": 0.33,
    "revenuecontractwithcustomer": 1,
    "options": 27002200,
    "classofwarrantorrightnumberofsecuritiescalledbywarrantsorrights": 375197640,
    "totalindollars": 402199840,
    "governmentauthorities": 47000,
    "prepaidexpenseandotherassets": 1123000,
    "otherreceivablesnetcurrent": 1170000,
    "propertyplantandequipmentgross": 290000,
    "accumulateddepreciationdepletionandamortizationpropertyplantandequipment": 248000,
    "employeesandpayrollaccruals": 492,
    "accruedliabilitiescurrentandnoncurrent": 283,
    "otheraccountspayableandaccruedliabilities": 775,
    "issuancedate": "December 2021",
    "classofwarrantorrightoutstanding": 375197640,
    "classofwarrantorrightexercisepriceofwarrantsorrights1": 0.07,
    "researchanddevelopmentexpenseexcludingacquiredinprocesscost": 137000,
    "othergeneralandadministrativeexpense": 126000,
    "sellinggeneralandadministrativeexpense": 263000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsriskfreeinterestrate": 0.0308,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsexpectedvolatilityrate": 0.8426,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsexpectedterm1": 10,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionexerciseprice": 3,
    "sharebasedpaymentawardfairvalueassumptionsexerciseprice": 0.25,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingnumber": 27002200,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageexerciseprice": 0.13,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageremainingcontractualterm2": 8.45,
    "sharebasedcompensationarrangementbysharebasedpaymentawardnonoptionequityinstrumentsother": 27002200,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsvestedandexpectedtovestoutstandingweightedaverageexerciseprice": 0.13,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsvestedandexpectedtovestoutstandingweightedaverageremainingcontractualterm1": 7.14,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexercisablenumber": 11071575,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingperiodincreasedecreaseweightedaverageexerciseprice": 0.21,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsexercisableweightedaverageremainingcontractualterm1": 7.18,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsgrantsinperiodgross": 8750000,
    "sharebasedcompensationarrangementsbysharebasedpaymentawardoptionsgrantsinperiodweightedaverageexerciseprice": 0.07,
    "sharebasedcompensationarrangementbysharebasedpaymentawardnonoptionequityinstrumentsforfeituresandexpirations": 170500,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsforfeituresandexpirationsinperiodweightedaverageexerciseprice": 0.54,
    "sharebasedcompensationsharesauthorizedunderstockoptionplansexercisepricerangeexercisableoptionsweightedaverageremainingcontractualterm2": 7.14,
    "operatingleaseweightedaverageremainingleaseterm1": 1.42,
    "operatingleaseweightedaveragediscountratepercent": 0.13,
    "operatingleasecost": 54000,
    "cashpaidforamountsincludedinthemeasurementofleaseliabilities": 54000,
    "lesseeoperatingleaseliabilitypaymentsdueyearthree": 54000,
    "lesseeoperatingleaseliabilitypaymentsdueyearfour": 18000,
    "lesseeoperatingleaseliabilitypaymentdue": 72000,
    "imputedinterestlessimputedinterest": 10000,
    "operatingleaseliability": 62000,
    "bankscommissions": -16000,
    "netlossfromexchangeratefluctuations": -54000,
    "otherlossfromshortterminvestmentrevaluation": -229000,
    "financeexpenses": -299000,
    "interestincomedepositswithfinancialinstitutions": 222000,
    "financeincome": 222000,
    "interestincomeexpensenet": -77000,
    "deferredtaxassetsoperatinglosscarryforwards": 25137000,
    "deferredtaxassetsinprocessresearchanddevelopment": 1376000,
    "deferredtaxassetsgross": 26513000,
    "deferredtaxassetsvaluationallowance": 26513000,
    "sharesissued": 10500000,
    "netlosses": 10173,
    "cashflowsfromoperatingactivities": -10801,
    "shorttermdebtweightedaverageinterestrateovertime": 0.0579,
    "contractliabilities": 3078000,
    "revenue": 810000,
    "percentageofdepositsonmonthlysalary": 0.0833,
    "severancecosts1": 51000,
    "percentageofrealizationonultimatesettlement": 0.5,
    "saleofstocknumberofsharesissuedintransaction": 5947,
    "percentageofoutstandingshares": 0.05,
    "depreciationexpenseonreclassifiedassets": 14,
    "additionalliabilitylongdurationinsurancebenefitpayment": 2000000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardawardvestingrightspercentage": 0.165,
    "amountofregulatoryassistancereceived1": 2000,
    "otherloanspayable": 14000,
    "percentageoffifoinventory": 0.23,
    "securitiesreceivedascollateral": 2250,
    "additionalpaidincapitalcommonstock": 600000,
    "deferredsalesinducementsnet": 58500,
    "paymentstosuppliers": 750,
    "additionalcollateralaggregatefairvalue": 3250,
    "noninterestexpensecommissionexpense": 25000,
    "royaltyexpense": 10000,
    "percentageofnetsales": -0.03,
    "advanceroyalties": 850000,
    "royaltypaymentspercentage": 0.1,
    "patentagreementdescription": "Royalties in a total amount of up to €850 thousand based on certain progress milestones in the license stages of the products, which are the subject of the patent under the agreement, as follows: (i) €50 thousand upon initiation of Phase I studies; (ii) €100 thousand upon initiation of Phase II studies; (iii) €200 thousand upon initiation of Phase III studies; and (iv) €500 thousand upon marketing approval by any regulatory authority.",
    "stockoptionexercisepriceincrease": 0.022,
    "acceleratedsharerepurchasesinitialpricepaidpershare": 0.07,
    "futureshares": 8023000,
    "sharebasedcompensationsharesauthorizedunderstockoptionplansexercisepricerangeoutstandingoptionsweightedaverageremainingcontractualterm2": 6.96,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsvestedweightedaveragegrantdatefairvalue": 0.02,
    "lesseeoperatingleaseremainingleaseterm": 3,
    "effectiveincometaxratecontinuingoperations": 0.23,
    "effectiveincometaxratereconciliationatfederalstatutoryincometaxrate": 0.16,
    "developmentareaapercentage": 0.075,
    "deferredtaxassetscapitallosscarryforwards": 157106,
    "relatedpartytransactionexpensesfromtransactionswithrelatedparty": 218000,
    "commonstockcapitalsharesreservedforfutureissuance": 28636500,
    "noninterestexpensetransferagentandcustodianfees": 675,
    "netofdirectissuancecosts": 6808,
    "entityregistrantname": "Can-FiteBioPharma Ltd.",
    "tradingsymbol": "CANF",
    "documenttype": "20-F",
    "currentfiscalyearenddate": "December 31",
    "entitycommonstocksharesoutstanding": 815746293,
    "amendmentflag": "false",
    "entitycentralindexkey": 1536196,
    "entitycurrentreportingstatus": "Yes",
    "entityvoluntaryfilers": "No",
    "entityfilercategory": "Non-accelerated filer",
    "entitywellknownseasonedissuer": "No",
    "documentperiodenddate": "December 31, 2022",
    "documentfiscalyearfocus": 2022,
    "documentfiscalperiodfocus": "FY",
    "entityemerginggrowthcompany": "false",
    "entityshellcompany": "No",
    "icfrauditorattestationflag": "false",
    "documentregistrationstatement": "false",
    "documentannualreport": "true",
    "documenttransitionreport": "false",
    "documentshellcompanyreport": "false",
    "entityfilenumber": "001-36203",
    "entityincorporationstatecountrycode": "Israel",
    "entityaddressaddressline1": "10Bareket Street",
    "entityaddressaddressline2": "Kiryat Matalon",
    "entityaddressaddressline3": "P.O. Box 7537",
    "entityaddresscityortown": "Petah-Tikva",
    "entityaddresspostalzipcode": 4951778,
    "entityaddresscountry": "Israel",
    "contactpersonnelname": "MottiFarbstein",
    "cityareacode": 972,
    "localphonenumber": "(3) 924-1114",
    "contactpersonnelfaxnumber": "972 (3) 924-9378",
    "contactpersonnelemailaddress": "motti@canfite.co.il",
    "security12btitle": "American Depositary Shares, each representing 300 Ordinary Shares, no par value *",
    "securityexchangename": "NYSE American",
    "entityinteractivedatacurrent": "Yes",
    "documentaccountingstandard": "U.S. GAAP",
    "auditorfirmid": 1281,
    "auditorname": "KOST FORER GABBAY& KASIERER",
    "auditorlocation": "Tel-Aviv,Israel"
  },
  {
    "date": "2021-12-31",
    "symbol": "CANF",
    "period": "FY",
    "cashandcashequivalentsatcarryingvalue": 4390000,
    "depositsassetscurrent": 14512000,
    "prepaidexpenseandotherassetscurrent": 929000,
    "shortterminvestments": 237000,
    "assetscurrent": 20068000,
    "operatingleaserightofuseasset": 138000,
    "propertyplantandequipmentnet": 47000,
    "assetsnoncurrent": 185000,
    "assets": 20253000,
    "accountspayabletradecurrent": 954000,
    "operatingleaseliabilitycurrent": 53000,
    "deferredrevenuecurrent": 818000,
    "accountspayableandotheraccruedliabilitiescurrent": 905000,
    "liabilitiescurrent": 2730000,
    "operatingleaseliabilitynoncurrent": 71000,
    "deferredrevenuenoncurrent": 3070000,
    "liabilitiesnoncurrent": 3141000,
    "commonstockvalue": 60654000,
    "additionalpaidincapital": 93275000,
    "accumulatedothercomprehensiveincomelossnetoftax": 1127000,
    "retainedearningsaccumulateddeficit": -140674000,
    "stockholdersequity": -140674000,
    "liabilitiesandstockholdersequity": 20253000,
    "commonstockparorstatedvaluepershare": 0.25,
    "commonstocksharesauthorized": 5000000000,
    "commonstocksharesissued": 815746293,
    "commonstocksharesoutstanding": 815746293,
    "revenues": 853000,
    "researchanddevelopmentexpense": 9850000,
    "generalandadministrativeexpense": 3845000,
    "operatingincomeloss": -12842000,
    "nonoperatingincomeexpense": 227000,
    "incomelossfromcontinuingoperationsbeforeincometaxesextraordinaryitemsnoncontrollinginterest": -12615000,
    "netincomeloss": -12615000,
    "redeemablepreferredstockdividends": 2590000,
    "comprehensiveincomenetoftaxincludingportionattributabletononcontrollinginterest": -15205000,
    "earningspersharebasicanddiluted": -0.03,
    "weightedaveragenumberofshareoutstandingbasicanddiluted": 553079638,
    "sharesoutstanding": 815746293,
    "issuanceofsharecapitalduetowarrantsexercisenetofissuanceexpenses": 11767000,
    "issuanceofsharecapitalduetowarrantsexercisenetofissuanceexpensesinshares": 293926830,
    "stockissuedduringperiodvalueother": 68000,
    "stockissuedduringperiodsharesother": 1050000,
    "stockissuedduringperiodvaluestockdividend": -2590000,
    "stockissuedduringperiodvalueissuanceofsharecapitalandwarrants": 8690000,
    "stockissuedduringperiodshareissuanceofsharecapitalandwarrants": 57000000,
    "stockissuedduringperiodvaluesharebasedcompensation": 398000,
    "warrantsnetofissueexpenses": 1307000,
    "stockissuedduringperiodvaluenetofissueexpenses": 980000,
    "depreciationdepletionandamortization": 14000,
    "increasedecreaseinotheroperatingassets": -55000,
    "increasedecreaseinprepaiddeferredexpenseandotherassets": -128000,
    "increasedecreaseinsharebasedpayment": 398000,
    "sharebasedcompensation": 68000,
    "increasedecreaseinchangesinfairvalueofshortterminvestment": 162000,
    "increasedecreaseinotheroperatingliabilities": -63000,
    "increasedecreaseinaccruedinterestreceivablenet": 12000,
    "othernoncashincomeexpense": 34000,
    "increasedecreaseinaccountspayabletrade": 393000,
    "increasedecreaseindeferredrevenue": 1398000,
    "increasedecreaseinotheraccountspayable": 574000,
    "netcashprovidedbyusedinoperatingactivities": -9858000,
    "paymentstoacquirepropertyplantandequipment": 11000,
    "paymentstoacquireotherinvestments": 14500000,
    "netcashprovidedbyusedininvestingactivities": -14511000,
    "proceedsfromissuanceofsharesunderincentiveandsharebasedcompensationplansincludingstockoptions": 20457000,
    "netcashprovidedbyusedinfinancingactivities": 20457000,
    "effectofexchangerateoncashandcashequivalents": 34000,
    "cashcashequivalentsrestrictedcashandrestrictedcashequivalentsperiodincreasedecreaseincludingexchangerateeffect": -3878000,
    "cashcashequivalentsrestrictedcashandrestrictedcashequivalentsincludingdisposalgroupanddiscontinuedoperations": 4390000,
    "rightofuseassetobtainedinexchangeforoperatingleaseliability": 120000,
    "paymentsofdividends": 2590000,
    "interestpaidnet": 18000,
    "otheraccountsreceivableandprepaidexpensestextblock": "NOTE 3:- OTHER ACCOUNTS RECEIVABLE ANDPREPAID EXPENSES ",
    "severancepaypolicytextblock": "    o. Severance pay:  ",
    "ordinarysharewarrantsclassificationandmeasurementpolicytextblock": "r.",
    "accountingpronouncementsnotyetadoptedpolicytextblock": "u.",
    "scheduleofusefullivesoftheassetstabletextblock": "            %      Mainly %                            Laboratory equipment and Leasehold improvements      10       10                              Computers, office furniture and equipment      6 - 33       33    ",
    "scheduleofmajorcustomerdataasapercentageoftotalrevenuestabletextblock": "            December 31,             2021      2020                            Cipher Pharmaceuticals      12%      20%      Chong Kun Dang Pharmaceuticals Corp.      24%      45%      Gebro Holding GmBH      23%      35%      Ewopharma AG      41%      -                                     100%      100%  ",
    "scheduleofotheraccountsreceivableandprepaidexpensestabletextblock": "            December 31,             2021      2020             USD                            Government authorities     $48      $18       Prepaid expenses and others     $881      $1,039                                    $929      $1,057   ",
    "scheduleofexpensestabletextblock": "            Year ended December 31,             2021      2020      2019             USD                                   Research and development expenses     $200      $159      $138       General and administrative expenses      198       158       132                                            $398      $317      $270    ",
    "scheduleofestimatedusingthebinomialoptionpricingmodeltabletextblock": "      Description         2021      2020                                Risk-free interest rate          1.22-1.28%      0.93-2.40%      Expected volatility            82.40-82.43%       65.63-78.77 %      Dividend yield          0       0       Contractual life          10       9.83 - 10       Early Exercise Multiple (Suboptimal Factor)          3      2.5 - 3       Exercise price (NIS)          0.25-0.253       0.25- 2.344    ",
    "usefullivesordepreciationratespropertyplantandequipments": 0.33,
    "revenuecontractwithcustomer": 1,
    "governmentauthorities": 48000,
    "prepaidexpenseandotherassets": 881000,
    "otherreceivablesnetcurrent": 929000,
    "propertyplantandequipmentgross": 281000,
    "accumulateddepreciationdepletionandamortizationpropertyplantandequipment": 234000,
    "employeesandpayrollaccruals": 603,
    "accruedliabilitiescurrentandnoncurrent": 302,
    "otheraccountspayableandaccruedliabilities": 905,
    "issuancedate": "December 2021",
    "classofwarrantorrightoutstanding": 12598254,
    "classofwarrantorrightexercisepriceofwarrantsorrights1": 2,
    "researchanddevelopmentexpenseexcludingacquiredinprocesscost": 200000,
    "othergeneralandadministrativeexpense": 198000,
    "sharebasedpayments": 398000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsriskfreeinterestrate": 0.0128,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsexpectedvolatilityrate": 0.8243,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsexpectedterm1": 10,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsexerciseprice": 3,
    "sharebasedpaymentawardfairvalueassumptionsexerciseprice": 0.253,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingnumber": 18422700,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageexerciseprice": 0.18,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsgrantsinperiodgross": 7100000,
    "sharebasedcompensationarrangementsbysharebasedpaymentawardoptionsgrantsinperiodweightedaverageexerciseprice": 0.08,
    "sharebasedcompensationarrangementbysharebasedpaymentawardnonoptionequityinstrumentsforfeituresandexpirations": 600700,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsforfeituresandexpirationsinperiodweightedaverageexerciseprice": 1,
    "numberofexercisableatendofshares": 6322700,
    "weightedaverageexercisepriceexercisableatendofpershares": 0.35,
    "sharebasedpaymentarrangementoptionexercisepricerange": 5.18,
    "sharebasedcompensationsharesauthorizedunderstockoptionplansexercisepricerangenumberofoutstandingoptions": 18422700,
    "sharebasedcompensationsharesauthorizedunderstockoptionplansexercisepricerangeoutstandingoptionsweightedaverageremainingcontractualterm2": 0.01,
    "sharebasedcompensationsharesauthorizedunderstockoptionplansexercisepricerangeoutstandingoptionsweightedaverageexercisepricebeginningbalance1": 6322700,
    "sharebasedcompensationsharesauthorizedunderstockoptionplansexercisepricerangeexercisableoptionsweightedaverageexerciseprice1": 0.04,
    "sharebasedcompensationsharesauthorizedunderstockoptionplansexercisepricerangenumberofexercisableoptions": 0.01,
    "operatingleaseweightedaverageremainingleaseterm1": 2.42,
    "operatingleaseweightedaveragediscountratepercent": 0.13,
    "operatingleasecost": 55000,
    "cashpaidforamountsincludedinthemeasurementofleaseliabilities": 55000,
    "supplementalnoncashinformationrelatedtoleaseliabilitiesarisingfromobtainingrouassets": 120000,
    "lesseeoperatingleaseliabilitypaymentsdueyeartwo": 69000,
    "lesseeoperatingleaseliabilitypaymentsdueyearthree": 59000,
    "lesseeoperatingleaseliabilitypaymentsdueyearfour": 20000,
    "lesseeoperatingleaseliabilitypaymentdue": 148000,
    "imputedinterestlessimputedinterest": 24000,
    "operatingleaseliability": 124000,
    "bankscommissions": -18000,
    "otherexpenses": 4000,
    "financeexpenses": -22000,
    "interestincomedepositswithfinancialinstitutions": 24000,
    "exchangeratefluctuations": 59000,
    "gainlossoninvestments": 162000,
    "financeincome": 249000,
    "interestincomeexpensenet": 227000,
    "deferredtaxassetsoperatinglosscarryforwards": 37875000,
    "deferredtaxassetsinprocessresearchanddevelopment": 3285000,
    "deferredtaxassetsgross": 41160000,
    "deferredtaxassetsvaluationallowance": 41160000,
    "sharesissued": 30,
    "cashflowsfromoperatingactivities": -9858000,
    "debtweightedaverageinterestrate": 0.0053,
    "contractliabilities": 3888000,
    "revenue": 853000,
    "revenuesincludedincontractliabilities": 507000,
    "percentageofdepositsonmonthlysalary": 0.0833,
    "severancecosts1": 53000,
    "percentageofrealizationonultimatesettlement": 0.5,
    "antidilutivesecuritiesexcludedfromcomputationofearningspershareamount": 18422700,
    "saleofstocknumberofsharesissuedintransaction": 356803,
    "percentageofoutstandingshares": 0.05,
    "depreciationexpenseonreclassifiedassets": 14,
    "noninterestexpensecommissionexpense": 25000,
    "royaltyexpense": 10000,
    "percentageofnetsales": 0.03,
    "patentagreementdescription": "4)",
    "advanceroyalties": 850000,
    "royaltypaymentspercentage": 0.1,
    "futureshares": 6618500,
    "sharebasedcompensationsharesauthorizedunderstockoptionplansexercisepricerangeexercisableoptionsweightedaverageremainingcontractualterm2": 8.45,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsvestedweightedaveragegrantdatefairvalue": 0.18,
    "employeeservicesharebasedcompensationnonvestedawardstotalcompensationcostnotyetrecognized": 1139,
    "sharebasedcompensationarrangementbysharebasedpaymentawardequityinstrumentsotherthanoptionsoutstandingweightedaverageremainingcontractualterms": 2.82,
    "lesseeoperatingleaseremainingleaseterm": 3,
    "effectiveincometaxratecontinuingoperations": 0.23,
    "deferredtaxassetscapitallosscarryforwards": 164680,
    "relatedpartytransactionexpensesfromtransactionswithrelatedparty": 241000,
    "entityregistrantname": "Can-Fite BioPharma Ltd.",
    "tradingsymbol": "CANF",
    "documenttype": "20-F",
    "currentfiscalyearenddate": "December 31",
    "entitycommonstocksharesoutstanding": 815746293,
    "amendmentflag": "false",
    "entitycentralindexkey": 1536196,
    "entitycurrentreportingstatus": "Yes",
    "entityvoluntaryfilers": "No",
    "entityfilercategory": "Non-accelerated filer",
    "entitywellknownseasonedissuer": "No",
    "documentperiodenddate": "December 31, 2021",
    "documentfiscalyearfocus": 2021,
    "documentfiscalperiodfocus": "FY",
    "entityemerginggrowthcompany": "false",
    "entityshellcompany": "No",
    "icfrauditorattestationflag": "false",
    "documentregistrationstatement": "false",
    "documentannualreport": "true",
    "documenttransitionreport": "false",
    "documentshellcompanyreport": "false",
    "entityfilenumber": "001-36203",
    "entityincorporationstatecountrycode": "Israel",
    "entityaddressaddressline1": "10 Bareket Street",
    "entityaddressaddressline2": "Kiryat Matalon",
    "entityaddressaddressline3": "P.O. Box 7537",
    "entityaddresscityortown": "Petah-Tikva",
    "entityaddresspostalzipcode": 4951778,
    "entityaddresscountry": "Israel",
    "contactpersonnelname": "Motti Farbstein",
    "cityareacode": 972,
    "localphonenumber": "(3) 924-1114",
    "contactpersonnelfaxnumber": "972 (3) 924-9378",
    "contactpersonnelemailaddress": "motti@canfite.co.il",
    "security12btitle": "American Depositary Shares, each representing 30 Ordinary Shares, par value NIS 0.25 per share",
    "securityexchangename": "NYSE American",
    "entityinteractivedatacurrent": "Yes",
    "documentaccountingstandard": "U.S. GAAP",
    "auditorfirmid": 1281,
    "auditorname": "Kost Forer Gabbay & Kasierer",
    "auditorlocation": "Tel-Aviv, Israel"
  },
  {
    "date": "2020-12-31",
    "symbol": "CANF",
    "period": "FY",
    "cashandcashequivalentsatcarryingvalue": 8268000,
    "prepaidexpenseandotherassetscurrent": 1057000,
    "shortterminvestments": 75000,
    "assetscurrent": 9400000,
    "operatingleaserightofuseasset": 73000,
    "propertyplantandequipmentnet": 50000,
    "assetsnoncurrent": 123000,
    "assets": 9523000,
    "accountspayabletradecurrent": 561000,
    "operatingleaseliabilitycurrent": 43000,
    "deferredrevenuecurrent": 334000,
    "accountspayableandotheraccruedliabilitiescurrent": 331000,
    "liabilitiescurrent": 1269000,
    "operatingleaseliabilitynoncurrent": 24000,
    "deferredrevenuenoncurrent": 2156000,
    "liabilitiesnoncurrent": 2180000,
    "commonstockvalue": 33036000,
    "additionalpaidincapital": 97380000,
    "accumulatedothercomprehensiveincomelossnetoftax": 1127000,
    "retainedearningsaccumulateddeficit": -125469000,
    "stockholdersequity": -125469000,
    "liabilitiesandstockholdersequity": 9523000,
    "commonstockparorstatedvaluepershare": 0.25,
    "commonstocksharesauthorized": 1000000000,
    "commonstocksharesissued": 463769463,
    "commonstocksharesoutstanding": 463769463,
    "revenues": 763000,
    "researchanddevelopmentexpense": 11951000,
    "generalandadministrativeexpense": 2951000,
    "operatingincomeloss": -14139000,
    "nonoperatingincomeexpense": -304000,
    "incomelossfromcontinuingoperationsbeforeincometaxesextraordinaryitemsnoncontrollinginterest": -14443000,
    "netincomeloss": -14443000,
    "redeemablepreferredstockdividends": 715000,
    "comprehensiveincomenetoftaxincludingportionattributabletononcontrollinginterest": -15158000,
    "earningspersharebasicanddiluted": -0.04,
    "weightedaveragenumberofshareoutstandingbasicanddiluted": 358411297,
    "sharesoutstanding": 463769463,
    "stockissuedduringperiodvaluestockdividend": -715000,
    "stockissuedduringperiodvalueissuanceofsharecapitalandwarrants": 17683000,
    "stockissuedduringperiodshareissuanceofsharecapitalandwarrants": 341766780,
    "stockissuedduringperiodvaluenewissues": 75000,
    "stockissuedduringperiodsharesnewissues": 1350000,
    "stockissuedduringperiodvaluesharebasedcompensation": 317000,
    "stockissuedduringperiodvaluenetofissueexpenses": 3703000,
    "depreciationdepletionandamortization": 12000,
    "increasedecreaseinotheroperatingassets": -9000,
    "increasedecreaseinchangeinotherreceivables": -1549000,
    "increasedecreaseinsharebasedpayment": 355000,
    "increasedecreaseinchangesinfairvalueofshortterminvestment": 11000,
    "increasedecreaseinotheroperatingliabilities": -8000,
    "increasedecreaseincashandcashequivalents": -23000,
    "increasedecreaseinprepaiddeferredexpenseandotherassets": -2726000,
    "increasedecreaseinaccountspayabletrade": -1595000,
    "increasedecreaseindeferredrevenue": -401000,
    "increasedecreaseinotheraccountspayable": -279000,
    "netcashprovidedbyusedinoperatingactivities": -12063000,
    "paymentstoacquirepropertyplantandequipment": 26000,
    "netcashprovidedbyusedininvestingactivities": -26000,
    "proceedsfromissuanceofsharesunderincentiveandsharebasedcompensationplansincludingstockoptions": 17683000,
    "netcashprovidedbyusedinfinancingactivities": 17683000,
    "effectofexchangerateoncashandcashequivalents": -23000,
    "cashcashequivalentsrestrictedcashandrestrictedcashequivalentsperiodincreasedecreaseincludingexchangerateeffect": 5571000,
    "rightofuseassetobtainedinexchangeforoperatingleaseliability": 29000,
    "interestpaidnet": 23000,
    "usefullivesordepreciationratespropertyplantandequipments": 0.33,
    "governmentauthorities": 18000,
    "prepaidexpenseandotherassets": 1039000,
    "otherreceivablesnetcurrent": 1057000,
    "propertyplantandequipmentgross": 270000,
    "accumulateddepreciationdepletionandamortizationpropertyplantandequipment": 220000,
    "employeesandpayrollaccruals": 96000,
    "accruedliabilitiescurrentandnoncurrent": 235000,
    "otheraccountspayableandaccruedliabilities": 331000,
    "investmentsfairvaluedisclosure": 75000,
    "researchanddevelopmentexpenseexcludingacquiredinprocesscost": 159000,
    "othergeneralandadministrativeexpense": 158000,
    "sharebasedpayments": 317000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsriskfreeinterestrate": 0.024,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsexpectedvolatilityrate": 0.7877,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsexpectedterm1": "P10Y",
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsexerciseprice": 3,
    "sharebasedpaymentawardfairvalueassumptionsexerciseprice": 2.344,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingnumber": 11923400,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageexerciseprice": 0.28,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsgrantsinperiodgross": 9250000,
    "sharebasedcompensationarrangementsbysharebasedpaymentawardoptionsgrantsinperiodweightedaverageexerciseprice": 0.08,
    "numberofexercisableatendofshares": 2900276,
    "weightedaverageexercisepriceexercisableatendofpershares": 0.74,
    "sharebasedpaymentarrangementoptionexercisepricerange": 5.01,
    "sharebasedcompensationsharesauthorizedunderstockoptionplansexercisepricerangenumberofoutstandingoptions": 11923400,
    "sharebasedcompensationsharesauthorizedunderstockoptionplansexercisepricerangeoutstandingoptionsweightedaverageremainingcontractualterm2": "P7D",
    "sharebasedcompensationsharesauthorizedunderstockoptionplansexercisepricerangeoutstandingoptionsweightedaverageexercisepricebeginningbalance1": 2900276,
    "sharebasedcompensationsharesauthorizedunderstockoptionplansexercisepricerangeexercisableoptionsweightedaverageexerciseprice1": 0.26,
    "sharebasedcompensationsharesauthorizedunderstockoptionplansexercisepricerangenumberofexercisableoptions": 0.06,
    "operatingleaseweightedaverageremainingleaseterm1": "P1Y259D",
    "operatingleaseweightedaveragediscountratepercent": 0.13,
    "operatingleasecost": 43000,
    "leasecost": 43000,
    "cashpaidforamountsincludedinthemeasurementofleaseliabilities": 43000,
    "supplementalnoncashinformationrelatedtoleaseliabilitiesarisingfromobtainingrouassets": 29000,
    "lesseeoperatingleaseliabilitypaymentsduenexttwelvemonths": 45000,
    "lesseeoperatingleaseliabilitypaymentsdueyeartwo": 20000,
    "lesseeoperatingleaseliabilitypaymentsdueyearthree": 6000,
    "operatingleasesfutureminimumpaymentsdue": 71000,
    "imputedinterestlessimputedinterest": 4000,
    "operatingleaseliability": 67000,
    "bankscommissions": -23000,
    "investmentincomenetamortizationofdiscountandpremium": -363000,
    "financeexpenses": -386000,
    "interestincomedepositswithfinancialinstitutions": 44000,
    "exchangeratefluctuations": 28000,
    "gainlossoninvestments": 11000,
    "financeincome": 83000,
    "interestincomeexpensenet": -303000,
    "deferredtaxassetsoperatinglosscarryforwards": 32312000,
    "deferredtaxassetsinprocessresearchanddevelopment": 3581000,
    "deferredtaxassetsgross": 35893000,
    "deferredtaxassetsvaluationallowance": 35893000,
    "sharesissued": 30,
    "contractliabilities": 2490000,
    "percentageofdepositsonmonthlysalary": 0.0833,
    "severancecosts1": 46000,
    "percentageofrealizationonultimatesettlement": 0.5,
    "antidilutivesecuritiesexcludedfromcomputationofearningspershareamount": 11923400,
    "saleofstocknumberofsharesissuedintransaction": 356803,
    "percentageofoutstandingshares": 0.0106,
    "laboratoryservicesexpenses": 2199000,
    "depreciationexpenseonreclassifiedassets": 12000,
    "noninterestexpensecommissionexpense": 25000,
    "royaltyexpense": 10000,
    "percentageofnetsales": 0.03,
    "advanceroyalties": 850000,
    "patentagreementdescription": "the patent under the agreement, as follows: (i) &#x20ac;50 thousands upon initiation of Phase I studies; (ii) &#x20ac;100 thousands upon initiation of Phase II studies; (iii) &#x20ac;200 thousands upon initiation of Phase III studies; and (iv) &#x20ac;500 thousands upon marketing approval by any regulatory authority.",
    "royaltypaymentspercentage": 0.23,
    "capitalpointafeepercentage": 0.05,
    "stockissuedduringperiodsharesissuedforservices": 1350000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardnumberofsharesavailableforgrant": 13225000,
    "sharebasedcompensationsharesauthorizedunderstockoptionplansexercisepricerangeexercisableoptionsweightedaverageremainingcontractualterm2": "P6Y357D",
    "lesseeoperatingleaseremainingleaseterm": "P3Y",
    "effectiveincometaxratecontinuingoperations": 0.23,
    "deferredtaxassetscapitallosscarryforwards": 140485,
    "relatedpartytransactionexpensesfromtransactionswithrelatedparty": 252000,
    "entityregistrantname": "Can-Fite BioPharma Ltd.",
    "documenttype": "20-F",
    "currentfiscalyearenddate": "--12-31",
    "entitycommonstocksharesoutstanding": 463769463,
    "amendmentflag": "false",
    "entitycentralindexkey": 1536196,
    "entitycurrentreportingstatus": "Yes",
    "entityvoluntaryfilers": "No",
    "entityfilercategory": "Non-accelerated Filer",
    "entitywellknownseasonedissuer": "No",
    "documentperiodenddate": "2020-12-31",
    "documentfiscalyearfocus": 2020,
    "documentfiscalperiodfocus": "FY",
    "entityemerginggrowthcompany": "false",
    "entityshellcompany": "false",
    "documentannualreport": "true",
    "documenttransitionreport": "false",
    "documentshellcompanyreport": "false",
    "entityfilenumber": "001-36203",
    "entityincorporationstatecountrycode": "L3",
    "entityinteractivedatacurrent": "Yes"
  },
  {
    "date": "2019-12-31",
    "symbol": "CANF",
    "period": "FY",
    "entityregistrantname": "Can-Fite BioPharma Ltd.",
    "entitycentralindexkey": 1536196,
    "documenttype": "20-F",
    "documentperiodenddate": "2019-12-31",
    "amendmentflag": "false",
    "currentfiscalyearenddate": "--12-31",
    "documentfiscalperiodfocus": "FY",
    "documentfiscalyearfocus": 2019,
    "entitywellknownseasonedissuer": "No",
    "entityvoluntaryfilers": "No",
    "entitycurrentreportingstatus": "Yes",
    "entityfilercategory": "Non-accelerated Filer",
    "entityemerginggrowthcompany": "true",
    "entityextransitionperiod": "false",
    "entityshellcompany": "false",
    "entitycommonstocksharesoutstanding": 120652683,
    "documentannualreport": "true",
    "documenttransitionreport": "false",
    "documentshellcompanyreport": "false",
    "entityfilenumber": "001-36203",
    "entityinteractivedatacurrent": "Yes",
    "entityincorporationstatecountrycode": "L3",
    "cashandcashequivalents": 2697000,
    "othercurrentreceivables": 4383000,
    "shortterminvestment": 64000,
    "currentassets": 7144000,
    "noncurrentreceivables": 1549000,
    "rightofuseassets": 83000,
    "propertyplantandequipment": 5000,
    "noncurrentassets": 1031000,
    "assets": 8175000,
    "tradeandothercurrentpayablestotradesuppliers": 2156000,
    "currentleaseliabilities": 36000,
    "deferredincomeclassifiedascurrent": 469000,
    "othercurrentpayables": 610000,
    "currentliabilities": 3271000,
    "noncurrentleaseliabilities": 39000,
    "noncurrentwarrantsexercisableintoshares": 1566000,
    "deferredincomeclassifiedasnoncurrent": -10000,
    "noncurrentliabilities": 4027000,
    "issuedcapital": 8225000,
    "sharepremium": 95665000,
    "reserveofsharebasedpayments": 6070000,
    "accumulatedothercomprehensiveincome": 1127000,
    "retainedearnings": -110210000,
    "equity": -110210000,
    "equityandliabilities": 8175000,
    "revenue": 2032000,
    "administrativeexpense": 10976000,
    "generalandadministrativeexpense": 132000,
    "profitlossfromoperatingactivities": -12003000,
    "financecosts": 693000,
    "financeincome": 3109000,
    "financeincomeexpensesfromreinsurancecontractsheldrecognisedinprofitorloss": 2416000,
    "profitlossbeforetax": -9587000,
    "profitloss": -9587000,
    "comprehensiveincome": -9587000,
    "profitlossattributabletoownersofparent": -9587000,
    "comprehensiveincomeattributabletoownersofparent": -9587000,
    "basicanddilutedearningslosspershare": -0.11,
    "issuanceofsharecapitalandwarrants": 1546000,
    "issuanceofsharecapital": 43000,
    "increasedecreasethroughsharebasedpaymenttransactions": 270000,
    "shareissuerelatedcost": 1382000,
    "adjustmentofdepreciationpropertyplantandequipment": 42000,
    "adjustmentsfordecreaseincreaseintradeandotherreceivables": 201000,
    "adjustmentsforsharebasedpayments": 385000,
    "increasedecreaseinfairvalueofwarrantsliabilityexercisableintoshares": -3037000,
    "changesinfairvalueoflongterminvestment": 209000,
    "effectofexchangeratechangesoncashandcashequivalentsinoperatingactivies": -2000,
    "adjustmentsforreconcileprofitloss": -2202000,
    "adjustmentsforincreasedecreaseinaccountsreceivableprepaidexpensesandleasedeposit": 270000,
    "adjustmentsforincreasedecreaseintradeaccountpayable": 1085000,
    "adjustmentsforincreasedecreaseindeferredincome": 146000,
    "adjustmentsforincreasedecreaseinotheroperatingpayables": -512000,
    "adjustmentsforworkingcapitaltotal": 989000,
    "cashflowsfromusedinoperatingactivities": -10800000,
    "purchaseofpropertyplantandequipmentclassifiedasinvestingactivities": 3000,
    "increaseinotherreceivables": 250000,
    "cashflowsfromusedininvestingactivities": -253000,
    "paymentsofleaseliabilitiesclassifiedasfinancingactivities": 31000,
    "proceedsfromissuingshares": 10167000,
    "cashflowsfromusedinfinancingactivities": 10133000,
    "effectofexchangeratechangesoncashandcashequivalents": 2000,
    "increasedecreaseincashandcashequivalents": -918000,
    "interestpaidreceived": 72000,
    "cashpaidduringyearforinterest": 29000,
    "proportionofownershipinterestinjointventure": 0.82,
    "gainsondisposalsofinvestments": 769000,
    "usefullivesordepreciationratespropertyplantandequipments": 0.33,
    "percentageofdeposits": 0.0833,
    "descriptionofamericandepositaryshare": "Each ADS represents 2 ordinary shares of the Company",
    "righttouseasset": 19000,
    "currentgovernmentgrants": 14000,
    "currentassetrelatedtounivotransaction": 637000,
    "currentprepaidexpenses": 3732000,
    "totalinstallmentsamount": 500000,
    "increasedecreaseinnumberofordinarysharesissued": 19934355,
    "numberofoutstandingordinarysharespercentage": 0.166,
    "numberofsharesissued": 996690,
    "percentageofvotingequityinterestsacquired": 0.022,
    "initialrecognitionreceivable": 1750000,
    "partialrecognitionreceivable": -201000,
    "totalothernoncurrentreceivables": 1549000,
    "otherreceivables": 637000,
    "othernoncurrentreceivables": 912000,
    "fairvalueofshares": 1500000,
    "portionofconsiderationpaidreceivedconsistingofcashandcashequivalents": 250000,
    "laboratoryservices": 201000,
    "propertyplantandequipmentgrosscarryingamount": 12000,
    "accumulateddepreciationandamortisation": 7000,
    "depreciationpropertyplantandequipment": 1000,
    "depreciationexpense": 14000,
    "currentemployeerelatedliabilities": 165000,
    "currentaccruedexpensesandothercurrentliabilities": 445000,
    "financialassets": 64000,
    "financialliabilitiesatfairvaluethroughprofitorloss": 1566000,
    "averageforeignexchangerate": 9,
    "financialassetsatfairvalue": 1566000,
    "issuesfairvaluemeasurementassets": 4603000,
    "increasedecreaseinfairvaluemeasurementassets": -3037000,
    "descriptionofexpectedvolatilityshareoptionsgranted": 0.6522,
    "descriptionofriskfreeinterestrateshareoptionsgranted": 0.0171,
    "exercisepriceshareoptionsgranted": 4,
    "optionlifeshareoptionsgranted": "P5Y6M7D",
    "foreigncurrencychangesstrengtheningofincreasedequityandincomestatement": 0.1,
    "feeandcommissionincomeexpense": 25000,
    "royaltyexpense": 11000,
    "percentageofnetsales": 0.03,
    "descriptionofpatentagreement": "The patent under the agreement, as follows: (i) € 50 upon initiation of Phase I studies; (ii) € 100 upon initiation of Phase II studies; (iii) € 200 upon initiation of Phase III studies; and (iv) € 500 upon marketing approval by any regulatory authority.",
    "percentageofroyaltypayment": 0.1,
    "amountsreceivablerelatedpartytransactions": 400000,
    "numberofsharesauthorised": 500000000,
    "numberofsharesissuedandoutstanding": 120652683,
    "numberofsharesissuanceofsharecapital": 80253393,
    "numberofshareissuedandoutstanding": 120652683,
    "valueofshareissuedandoutstanding": 30163170000,
    "valueofissuancesharecapital": 20063348000,
    "descriptionofwarrantexercised": "The fair value of the warrants issued as part of the April 2019 Financing, as of commitment date and December 31, 2019 were USD 977 and USD 94, respectively.",
    "researchanddevelopmentexpenses": 138000,
    "sharebasedcompensationpayments": 270000,
    "numberofoutstandingshareoption": 2673400,
    "numberofshareoptiongrantedinsharebasedpaymentarrangement": 1240000,
    "numberofshareoptionforfeitedinsharebasedpaymentarrangement": -4000,
    "numberofshareoptionexercisableinsharebasedpaymentarrangement": 1134653,
    "weightedaverageexercisepriceofshareoptionoutstandinginsharebasedpaymentarrangements": 0.89,
    "weightedaverageexercisepriceofshareoptiongrantedinsharebasedpaymentarrangements": 0.44,
    "weightedaverageexercisepriceofshareoptionforfeitedinsharebasedpaymentarrangements": 5.98,
    "weightedaverageexercisepriceofshareoptionexercisableinsharebasedpaymentarrangements": 1.39,
    "weightedaverageremainingcontractuallifeofshareoptions": "P7Y11M4D",
    "rangeofexercisepricesforshares": 0.08,
    "additionstorightofuseassets": 92000,
    "depreciationrightofuseassets": 28000,
    "leaseliabilitiesadditions": 79000,
    "leaseliabilitiesaccretionofinterest": 8000,
    "noncurrentleaseliabilitiesone": 75000,
    "totalamountrecognizedinprofitorloss": 36000,
    "leaseterms": "P3Y",
    "clinicalandpreclinicaltrial": 10290000,
    "wagesandsalaries": 814000,
    "patents": 163000,
    "materialexpense": 40000,
    "rentalexpense": 51000,
    "depreciationsexpense": 5000,
    "researchanddevelopmentotherincomeexpenses": -398000,
    "researchanddevelopmentexpense": 10976000,
    "professionalfeesexpense": 1167000,
    "investorsandpublicrelationsexpense": 281000,
    "salaryandrelatedexpenses": 570000,
    "directorsremunerationexpense": 175000,
    "rentexpenses": 34000,
    "travelexpense": 156000,
    "insuranceexpense": 383000,
    "stockexchangefess": 63000,
    "officeandcomputermaintenance": 83000,
    "repairsandmaintenanceexpense": 15000,
    "depreciationexpenses": 9000,
    "generalandadministrativeexpensesothers": 123000,
    "sellinggeneralandadministrativeexpense": 3059000,
    "feeandcommissionexpense": 21000,
    "postemploymentbenefitexpensedefinedbenefitplans": 8000,
    "interestexpensesfromimplementetion": -427000,
    "netforeignexchangeloss": 28000,
    "otherlossfromlongterminvestmentrevaluation": -209000,
    "interestincomeondeposits": 72000,
    "gainsonchangeinfairvalueofderivatives": 3037000,
    "adjustmentsforfinanceincomecost": -621000,
    "weightedaverageshares": 85909859,
    "profitlossattributabletoordinaryequityholdersofparententityincludingdilutiveeffects": 9587000,
    "dilutiveeffectofconvertibleinstrumentsonnumberofordinaryshares": 2673400,
    "applicabletaxrate": 0.23,
    "netoperatinglossescarryforward": 118642000,
    "managementandconsultingfees": 365000,
    "otherexpensesandsharebasedpayment": 83000,
    "patentexpensesandsharebasedpayment": 163000,
    "directorsfeesandsharebasedpayment": 175000,
    "numberofrelatedparty": 1,
    "numberofdirector": 5
  }
]